Highlights
- Market Cap
- $46.59B
- Enterprise Value
- $43.78B
- EPS (TTM)
- $1.83
- PE Ratio
- 43.79
- PEG Ratio
- 1.41
- Total Revenue (TTM)
- $6.07B
- Gross Profit (TTM)
- $4.74B
- EBITDA (TTM)
- $1.35B
- Year Range
- $65.94 - $87.89
- Target Price
- $96.38
- ROA (TTM)
- 7.81%
- ROE (TTM)
- 10.35%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Edwards Lifesciences Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Edwards Lifesciences Corporation (EW) has returned -6.06% so far this year and 10.49% over the past 12 months. Over the last ten years, EW has returned 10.33% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Edwards Lifesciences Corporation
- 1D
- 0.73%
- 1M
- -7.39%
- YTD
- -6.06%
- 6M
- 2.97%
- 1Y
- 10.49%
- 3Y*
- -1.08%
- 5Y*
- -0.91%
- 10Y*
- 10.33%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 27, 2000, EW's average daily return is +0.08%, while the average monthly return is +1.69%. At this rate, your investment would double in approximately 3.4 years.
Historically, 61% of months were positive and 39% were negative. The best month was May 2000 with a return of +35.4%, while the worst month was Oct 2000 at -38.4%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 4 months.
On a daily basis, EW closed higher 52% of trading days. The best single day was Jul 24, 2002 with a return of +17.9%, while the worst single day was Oct 31, 2000 at -41.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.56% | 6.28% | -7.39% | -6.06% | |||||||||
| 2025 | -2.13% | -1.15% | 1.20% | 4.15% | 3.62% | -0.01% | 1.41% | 2.56% | -4.39% | 6.02% | 5.12% | -1.64% | 15.16% |
| 2024 | 2.91% | 8.16% | 12.60% | -11.40% | 2.62% | 6.31% | -31.74% | 10.96% | -5.67% | 1.55% | 6.48% | 3.76% | -2.91% |
| 2023 | 2.80% | 4.88% | 2.85% | 6.35% | -4.26% | 11.99% | -13.00% | -6.82% | -9.40% | -8.03% | 6.26% | 12.61% | 2.20% |
| 2022 | -15.71% | 2.90% | 4.76% | -10.14% | -4.66% | -5.71% | 5.73% | -10.38% | -8.29% | -12.34% | 6.65% | -3.42% | -42.41% |
| 2021 | -9.48% | 0.63% | 0.65% | 14.20% | 0.40% | 8.00% | 8.40% | 4.37% | -3.39% | 5.84% | -10.44% | 20.73% | 42.00% |
Benchmark Metrics
Edwards Lifesciences Corporation has an annualized alpha of 17.46%, beta of 0.71, and R² of 0.17 versus S&P 500 Index. Calculated based on daily prices since March 28, 2000.
- This stock captured 104.87% of S&P 500 Index gains but only 54.02% of its losses — a favorable profile for investors.
- R² of 0.17 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 17.46%
- Beta
- 0.71
- R²
- 0.17
- Upside Capture
- 104.87%
- Downside Capture
- 54.02%
Return for Risk
Risk / Return Rank
EW ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and compare them to a chosen benchmark (S&P 500 Index).
| EW | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.44 | 0.90 | -0.46 |
Sortino ratioReturn per unit of downside risk | 0.83 | 1.39 | -0.56 |
Omega ratioGain probability vs. loss probability | 1.10 | 1.21 | -0.11 |
Calmar ratioReturn relative to maximum drawdown | 1.02 | 1.40 | -0.38 |
Martin ratioReturn relative to average drawdown | 2.82 | 6.61 | -3.79 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore EW risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Edwards Lifesciences Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Edwards Lifesciences Corporation was 54.32%, occurring on Jul 25, 2024. The portfolio has not yet recovered.
The current Edwards Lifesciences Corporation drawdown is 38.72%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -54.32% | Dec 31, 2021 | 644 | Jul 25, 2024 | — | — | — |
| -50.48% | Sep 1, 2000 | 43 | Nov 1, 2000 | 165 | Jun 29, 2001 | 208 |
| -44.02% | Oct 5, 2012 | 299 | Dec 13, 2013 | 217 | Oct 24, 2014 | 516 |
| -37.11% | Feb 12, 2002 | 112 | Jul 23, 2002 | 199 | May 7, 2003 | 311 |
| -36.15% | Nov 29, 2019 | 78 | Mar 23, 2020 | 110 | Aug 27, 2020 | 188 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Edwards Lifesciences Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Edwards Lifesciences Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for EW, comparing it with other companies in the Medical Devices industry. Currently, EW has a P/E ratio of 43.8. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for EW compared to other companies in the Medical Devices industry. EW currently has a PEG ratio of 1.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EW relative to other companies in the Medical Devices industry. Currently, EW has a P/S ratio of 7.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EW in comparison with other companies in the Medical Devices industry. Currently, EW has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |